The effect of anti-pd-1/pd-l1 antibodies combined with vegf receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma

HIGHLIGHTS

• who: Hui Zeng et al. from the Nanjing Medical University, China have published the research: The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma, in the Journal: (JOURNAL) of May/15,/2022
• what: The authors aimed to compare the efficacy and safety of ICI plus VEGF receptor (VGFR) TKI or bevacizumab as first-line treatment for uHCC and explore the potential advantages of the two models. Third, this study had a small sample size and few events.
• how: Categorical data . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.